MARKET

NLNK

NLNK

NewLink Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.720
+0.200
+13.16%
After Hours: 1.730 +0.01 +0.58% 17:24 12/09 EST
OPEN
1.580
PREV CLOSE
1.520
HIGH
1.815
LOW
1.520
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
2.270
52 WEEK LOW
1.130
MARKET CAP
64.18M
P/E (TTM)
-1.4158
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NLNK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NLNK News

  • Edited Transcript of NLNK earnings conference call or presentation 6-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/12 23:11
  • NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)
  • GlobeNewswire.11/12 14:00
  • NewLink Genetics Corporation (NLNK) Management on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/08 18:04
  • NewLink Genetics reports Q3 results
  • seekingalpha.11/06 18:12

More

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About NLNK

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
More

Webull offers NewLink Genetics Corp (NLNK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.